Blog

Precision Medicine: What can we learn from precision oncology clinical trials?

2019-08-07T14:54:49+00:00By |

To execute precision medicine clinical trials, sponsors have adopted a range of new approaches, especially in early-stage studies. Many of these models allow sponsors to recruit more patients and bring drugs to market faster— goals drug developers in all therapeutic areas work toward.

Comments Off on Precision Medicine: What can we learn from precision oncology clinical trials?

How to Use Proven Methodologies to Develop Successful Clinical Research Programs

2019-08-06T14:29:28+00:00By |

As clinical trials become more complex and costly, the need for skilled project managers to oversee them is more important than ever. Project management methodologies drive success for enterprise organizations in all sectors. These same principles can help pharmaceutical and biotech companies run more efficient, successful clinical trials.

Comments Off on How to Use Proven Methodologies to Develop Successful Clinical Research Programs

Orphan Drugs and Rare Diseases Global Congress 2019 Americas

2019-07-24T16:37:48+00:00By |

Biorasi will be at the 2019 Orphan Drugs and Rare Diseases 2019 Americas – West Coast from July 23rd - 24th 2019 in San Francisco, CA, USA. We would like to extend a cordial invitation to all of our partners, sponsors, and friends to come talk to us!. We will be showcasing how Biorasi is a new kind of CRO in how we manage clinical trials, as well as providing information on our Rare Disease Study expertise.

Comments Off on Orphan Drugs and Rare Diseases Global Congress 2019 Americas

FSGS: A rare kidney disease without targeted therapies

2019-07-18T10:20:21+00:00By |

Researchers are studying a few new and existing drugs to treat FSGS. FSGS needs a novel medication that regulates both high body fats and inflammasome inhibition via upstream innate immune system to block intracellular initiation of inflammatory cascade and extra cellular inflammation. Over the past five years, nearly 30% of Biorasi-initiated or ongoing studies involved chronic kidney disease. Our experience allows us to develop successful nephrology clinical trials.

Comments Off on FSGS: A rare kidney disease without targeted therapies

Is targeted gene therapy in Neurology’s future?

2019-07-26T12:41:24+00:00By |

To unlock more targeted, effective treatments, genetics researchers are exploring mutations responsible for some of the most common motor neuron diseases. These discoveries may lead to gene therapy treatment routes that do a better job of slowing disease progression than current medications. Much like gene therapy in oncology has brought improvement in cancer regression in recent years, we believe gene therapy—particularly therapy that targets and modulates RNA—is the future of neurology.

Comments Off on Is targeted gene therapy in Neurology’s future?

Biorasi Center of Excellence Spotlight: Oncology

2019-07-26T12:42:20+00:00By |

Biorasi’s Oncology Center of Excellence remains at the forefront of this exciting field. Our team of clinicians, program managers and other experts stay up to date on the latest developments, from Tumor Infiltrating Lymphocyte (TIL) therapy to gene therapy advances. This experience, combined with Biorasi’s worldwide site network and data-driven approach, allows us to guide oncology programs to success—on time and on budget.

Comments Off on Biorasi Center of Excellence Spotlight: Oncology

How Dermatology Research Gaps Represent Untapped Markets for Pharmaceutical Companies

2019-07-15T11:12:17+00:00By |

Gaps in dermatological research present potentially lucrative market opportunities for pharmaceutical companies. Patients that suffer from skin conditions and diseases also benefit. Effective treatments relieve irritating, chronic, and often painful symptoms, which improves their quality of life and lifts the psychological and social burden of a visible dermatological issue.

Comments Off on How Dermatology Research Gaps Represent Untapped Markets for Pharmaceutical Companies

How to Launch a Successful, Cost-Effective Neurodevelopmental Study

2019-07-26T12:54:11+00:00By |

How to run a more efficient pediatric clinical trial: Although pediatric trials overall cost roughly the same as adult clinical trials according to one analysis, they generally produce a more modest return on investment. To ensure your neurodevelopmental or other pediatric study completes in a cost-effective, efficient manner, follow these tips:

Comments Off on How to Launch a Successful, Cost-Effective Neurodevelopmental Study

Download our Precision Medicine Checklist

Complete the form below to receive a link to download this checklist
close-link

Schedule a call with one of our experts today

Let us know how we can help. Complete the form below and we will schedule a call
close-link

Start your FREE Trial Rescue Assessment!

Complete the form below and we will provide our free trial rescue assessment.
close-link

Download our Patient-Centric Trials White Paper

Complete the form below to receive a link to download this white paper
close-link

Download our Data Science White Paper

Complete the form below to receive a link to download this white paper
close-link

Schedule a TALOS™ Control Center Demo

Complete the form below to schedule a demo with our program development team
close-link

Download our Rare Disease Checklist

Complete the form below to receive a link to download this checklist
close-link

Download our Dermatology White Paper

Complete the form below to receive a link to download this white paper
close-link

Get Access to "Making Most of Trial Data" Webinar

Complete the form below to receive a link to access this webinar
close-link

Download our Precision Oncology White Paper

Complete the form below to receive a link to download this whitepaper
close-link